Related Experiment Video
Updated: Aug 17, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with
Wim H J Kruit1, Heidi H van Ojik, Vincent G Brichard
1Erasmus Medical Center-Daniel den Hoed Cancer Center, Department of Internal Oncology, Rotterdam, The Netherlands.
Abstract:
The purpose of this phase 1/2 study was to evaluate toxicity, tumor evolution and immunologic response following administration of a fixed dose of a recombinant MAGE-3 protein by subcutaneous and intradermal routes in the absence of immunologic adjuvant. Thirty-two patients with detectable metastatic melanoma expressing gene MAGE-3 were included and 30 received at least one injection with a fixed dose of a ProtD-MAGE-3 fusion protein. The immunization schedule included 6 intradermal and subcutaneous injections at 3-week intervals. Afterward, patients without major tumor progression who required other treatments received additional vaccinations at increasing time intervals. The vaccine was generally well tolerated. Among the 26 patients who received at least 4 vaccinations, we observed 1 partial response and 4 mixed responses. For these 5 responding patients, time to progression varied from 3.5 to 51+ months. An anti-MAGE-3 CD4 T-lymphocyte response was detected in 1 out of the 5 responding patients. The majority of patients had no anti-MAGE-3 antibody response. The clinical and immunologic responses generated by the vaccine are rather limited. Nevertheless, given the potential antitumor efficacy and the very mild toxicity of vaccinations, further studies combining MAGE proteins and/or peptides with potent immunologic adjuvants are warranted, not only in metastatic melanoma, but also in the adjuvant setting.
Insights
This study evaluated a MAGE-3 protein vaccine for metastatic melanoma. While generally well-tolerated, the vaccine showed limited clinical and immune responses, suggesting a need for adjuvant combinations.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Metastatic melanoma remains a significant challenge in cancer treatment.
- MAGE-3 is a tumor antigen expressed in melanoma, making it a target for immunotherapy.
- Recombinant protein vaccines offer a potential strategy for cancer treatment.
Purpose of the Study:
- To assess the toxicity, tumor evolution, and immunologic response of a fixed-dose recombinant MAGE-3 protein vaccine.
- To evaluate the efficacy of subcutaneous and intradermal administration without an immunologic adjuvant.
- To explore the potential of MAGE-3 protein in treating patients with metastatic melanoma.
Main Methods:
- A phase 1/2 study involving 32 patients with MAGE-3 expressing metastatic melanoma.
- Administration of a ProtD-MAGE-3 fusion protein via 6 intradermal and subcutaneous injections at 3-week intervals.
- Monitoring of toxicity, tumor response, and immunologic markers (CD4 T-lymphocyte and antibody responses).
Main Results:
- The vaccine was generally well tolerated with very mild toxicity.
- Among 26 patients receiving at least 4 vaccinations, 1 partial and 4 mixed responses were observed.
- Limited anti-MAGE-3 CD4 T-lymphocyte response (1/5) and minimal antibody response were detected.
Conclusions:
- The MAGE-3 protein vaccine demonstrated limited clinical and immunologic efficacy in metastatic melanoma.
- The vaccine's mild toxicity profile supports further investigation.
- Future studies should explore combining MAGE proteins with potent immunologic adjuvants for enhanced antitumor efficacy.
